1. FDA Releases Two Discussion Papers to Spur Conversation about Artificial Intelligence and Machine Learning in Drug Development and Manufacturing.
- Subjects
ARTIFICIAL intelligence ,MACHINE learning ,DRUG factories ,DRUG development ,RECOMBINANT proteins - Abstract
The regulatory uses are real: In 2021, more than 100 drug and biologic applications submitted to the FDA included AI/ML components. Keywords: Algorithms; Artificial Intelligence; Bioengineering; Biologics; Biotechnology; Cybersecurity; Cyborgs; Drug Development; Drug Manufacturing; Drugs and Therapies; Emerging Technologies; FDA; Genetic Engineering; Genetically-Engineered Proteins; Government Agencies Offices and Entities; Health and Medicine; Machine Learning; Office of the FDA Commissioner; Public Health; Technology; U.S. Food and Drug Administration EN Algorithms Artificial Intelligence Bioengineering Biologics Biotechnology Cybersecurity Cyborgs Drug Development Drug Manufacturing Drugs and Therapies Emerging Technologies FDA Genetic Engineering Genetically-Engineered Proteins Government Agencies Offices and Entities Health and Medicine Machine Learning Office of the FDA Commissioner Public Health Technology U.S. Food and Drug Administration 497 497 1 05/22/23 20230523 NES 230523 2023 MAY 22 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- By: Patrizia Cavazzoni, M.D., Director of the Center for Drug Evaluation and Research Artificial intelligence (AI) and machine learning (ML) are no longer futuristic concepts; they are now part of how we live and work. [Extracted from the article]
- Published
- 2023